Media headlines about Invacare (NYSE:IVC) have trended somewhat positive on Wednesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invacare earned a news impact score of 0.21 on Accern’s scale. Accern also assigned press coverage about the health services provider an impact score of 47.2860344867555 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Invacare (NYSE IVC) opened at $18.30 on Wednesday. The firm has a market cap of $717.12, a P/E ratio of -7.79 and a beta of 2.55. Invacare has a 1-year low of $10.20 and a 1-year high of $19.05. The company has a current ratio of 2.10, a quick ratio of 1.54 and a debt-to-equity ratio of 0.57.
Invacare (NYSE:IVC) last issued its earnings results on Wednesday, February 7th. The health services provider reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.02. The firm had revenue of $250.35 million during the quarter, compared to analysts’ expectations of $241.07 million. Invacare had a negative net margin of 7.92% and a negative return on equity of 14.95%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.46) earnings per share. equities research analysts predict that Invacare will post -1.16 EPS for the current fiscal year.
Several research analysts have recently issued reports on the stock. KeyCorp reiterated a “buy” rating and issued a $18.00 price objective on shares of Invacare in a report on Friday, November 10th. ValuEngine upgraded shares of Invacare from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research cut shares of Invacare from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. Invacare has an average rating of “Hold” and an average target price of $16.50.
In related news, Director C Martin Harris sold 3,443 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $18.15, for a total transaction of $62,490.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/21/invacare-ivc-earning-somewhat-favorable-press-coverage-study-finds.html.
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific.
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.